Search results
Showing 251 to 300 of 1895 results for carers
In development [GID-TA11156] Expected publication date: 19 June 2024
In development [GID-TA11039] Expected publication date: 19 June 2024
In development [GID-TA10992] Expected publication date: 15 May 2024
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
This quality standard covers preventing children and young people (under 18) from becoming overweight or obese, including strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for children and young people who are overweight or obese. It describes high-quality care in priority areas for improvement.
View quality statements for QS94Show all sections
Sections for QS94
- Introduction
- List of quality statements
- Quality statement 1: Vending machines
- Quality statement 2: Nutritional information at the point of choosing food and drink options
- Quality statement 3: Prominent placement of healthy options
- Quality statement 4: Maintaining details of local lifestyle weight management programmes
- Quality statement 5: Raising awareness of lifestyle weight management programmes
- Quality statement 6: Family involvement in lifestyle weight management programmes
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.
View quality statements for QS2Show all sections
Sections for QS2
- Quality statements
- Quality statement 1: Prompt admission to specialist acute stroke units
- Quality statement 2: Intensity of stroke rehabilitation
- Quality statement 3: Access to a clinical psychologist
- Quality statement 4: Early supported discharge
- Quality statement 5: Return to work
- Quality statement 6: Regular review of rehabilitation goals
- Quality statement 7: Regular review of health and social care needs
In development [GID-TA11186] Expected publication date: TBC
This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
In development [GID-TA10962] Expected publication date: 17 July 2024
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]
In development [GID-TA11349] Expected publication date: TBC
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
standard principles of infection prevention and control that patients and carers experience in their own homes? Any explanatory notes(if...
In development [GID-TA10979] Expected publication date: TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
In development [GID-TA11304] Expected publication date: 11 September 2024
Healthcare-associated infections: prevention and control in primary and community care (CG139)
This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
In development [GID-TA11250] Expected publication date: TBC
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
Improving outcomes for people with skin tumours including melanoma (CSG8)
This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.
This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS85Show all sections
Sections for QS85
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development [GID-TA11228] Expected publication date: 25 September 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
In development [GID-TA11135] Expected publication date: TBC
In development [GID-TA11174] Expected publication date: 16 October 2024
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
Find out what a NICE lay members does
In development [GID-TA11480] Expected publication date: 13 November 2024
In development [GID-TA11364] Expected publication date: TBC
In development [GID-TA11348] Expected publication date: TBC
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
In development [GID-TA11436] Expected publication date: 11 December 2024
In development [GID-TA11187] Expected publication date: TBC
In development [GID-TA11418] Expected publication date: 11 September 2024
Awaiting development [GID-TA11398] Expected publication date: 13 November 2024
In development [GID-TA11221] Expected publication date: 11 September 2024
Question Support to carers and practitioners to help young people's independence:- What is the most effective way to help...
In development [GID-TA10883] Expected publication date: 18 September 2024
In development [GID-TA11090] Expected publication date: TBC
In development [GID-HST10059] Expected publication date: 18 December 2024
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: 24 July 2024
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1 (developmental): Objective tests to support diagnosis
- Quality statement 2: Written personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
In development [GID-TA11384] Expected publication date: 13 November 2024
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
In development [GID-TA11423] Expected publication date: 11 December 2024
In development [GID-TA11408] Expected publication date: TBC
In development [GID-TA11359] Expected publication date: 11 December 2024
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
This quality standard covers recognising and managing faltering growth in babies (aged up to 1 year) and preschool children (aged over 1 year). It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
A selection of resources to help you deliver high-quality care and services using NICE guidance
Borderline personality disorder: recognition and management (CG78)
This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.